RVTY Revvity Inc.

Revvity Q2 EPS of $1.18 beat the $1.14 estimate; revenue rose to $720.28 million, topping $710.71 million consensus. FY25 EPS guidance trimmed to $4.85-$4.95 from $4.90-$5.00 due to China DRG policy headwinds. Missed the rally? Learn exactly where the next leaders are emerging here. Revvity Inc.

Revvity's second-quarter results showcase strong growth in its Diagnostics business, along with recovery in Life Sciences segmental sales.

U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 0.3% on Monday. Shares of ATAI Life Sciences NV ATAI fell sharply in pre-market trading after the company announced the Phase 2b trial of Inidascamine in patients with cognitive impairment associated with ...

Revvity ( NYSE:RVTY ) , a global provider of life sciences and diagnostics tools, released its results for Q2 2025 on July 28, 2025. The company reported GAAP revenue of $720 million, surpassing Wall Street's GAAP estimate of $710.37 million.

Revvity (RVTY) delivered earnings and revenue surprises of +3.51% and +1.27%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Revvity (RVTY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.